Using Bayesian Dynamic Borrowing to Maximize the Use of Existing Data: A Case-Study

Area of Science:

• Clinical Drug Development
• Biostatistics
• Regulatory Science

Background:

• Bayesian Dynamic Borrowing (BDB) is increasingly adopted in clinical trials.
• BDB offers a mathematically rigorous method for integrating existing data into new trials.
• Regulatory acceptance of BDB is evolving and varies across agencies.

Purpose of the Study:

• To describe the design of a new randomized clinical trial using BDB with external data.
• To discuss key considerations for data re-use and BDB in drug development programs.
• To present a case study on BDB for drug registration in China.

Main Methods:

• Designing a randomized clinical trial incorporating external data via BDB.
• Evaluating the appropriateness, selection, and weighting of external data for borrowing.
• Assessing the successful demonstration of treatment benefit in the new study.

Main Results:

• The paper details the application of BDB in designing clinical trials.
• It addresses critical factors for effective data borrowing and integration.
• A case study illustrates BDB's role in supporting drug registration.

Conclusions:

• BDB provides a powerful framework for efficient and evidence-based clinical drug development.
• Careful consideration of data selection, weighting, and regulatory guidelines is crucial for BDB implementation.
• The presented case study demonstrates the practical application and evaluation of BDB in a regulatory context.